• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Effect of diluted povidone iodine in adenoviral keratoconjunctivitis on the rate of subepithelial corneal infiltrates.稀释聚维酮碘治疗腺病毒性角结膜炎对角膜上皮下浸润发生率的影响。
Int J Ophthalmol. 2019 Sep 18;12(9):1420-1425. doi: 10.18240/ijo.2019.09.08. eCollection 2019.
2
The effect of povidone-iodine 2% eye drops in the treatment of adenoviral keratoconjunctivitis.2%聚维酮碘滴眼液治疗腺病毒性角结膜炎的效果
Oman J Ophthalmol. 2023 Feb 21;16(1):69-74. doi: 10.4103/ojo.ojo_180_22. eCollection 2023 Jan-Apr.
3
Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study.1.0%聚维酮碘与0.1%地塞米松滴眼液联合治疗腺病毒性角结膜炎:一项临床前瞻性对照随机研究
Acta Ophthalmol. 2017 Dec;95(8):e686-e692. doi: 10.1111/aos.13416. Epub 2017 Mar 25.
4
Comparison between the Efficacy and Tolerability of Polyvinylpyrrolidone-Iodine Eye Drops 0.6% and 1% in Adenoviral Keratoconjunctivitis: A Randomized Clinical Trial.0.6%和1%聚维酮碘滴眼液治疗腺病毒性角结膜炎的疗效与耐受性比较:一项随机临床试验
J Curr Ophthalmol. 2024 Aug 10;35(4):337-344. doi: 10.4103/joco.joco_251_23. eCollection 2023 Oct-Dec.
5
Efficacy and tolerability of polyvinylpyrrolidone-iodine 0.6% treatment in adenoviral keratoconjunctivitis: a Prospective Randomized Controlled Study.聚维酮碘 0.6%治疗腺病毒性角结膜炎的疗效和耐受性:一项前瞻性随机对照研究。
Eye (Lond). 2022 Jan;36(1):160-166. doi: 10.1038/s41433-020-01344-6. Epub 2021 Mar 2.
6
A treatment protocol for minimizing duration and complications of adenoviral epidemic keratoconjunctivitis.一种将腺病毒性流行性角结膜炎的病程和并发症降至最低的治疗方案。
Taiwan J Ophthalmol. 2019 Oct 24;10(4):269-277. doi: 10.4103/tjo.tjo_66_19. eCollection 2020 Oct-Dec.
7
Povidone iodine in the treatment of adenoviral conjunctivitis in infants.聚维酮碘治疗婴儿腺病毒性结膜炎
Cutan Ocul Toxicol. 2015 Mar;34(1):12-5. doi: 10.3109/15569527.2014.888077. Epub 2014 Mar 31.
8
The Relationship between Clinical Findings and Viral Load in Adenoviral Keratoconjunctivitis.腺病毒性角结膜炎的临床发现与病毒载量之间的关系
Jpn J Infect Dis. 2022 Nov 22;75(6):592-596. doi: 10.7883/yoken.JJID.2022.210. Epub 2022 Jul 29.
9
Management of Adenoviral Keratoconjunctivitis: Challenges and Solutions.腺病毒性角结膜炎的管理:挑战与解决方案
Clin Ophthalmol. 2020 Mar 17;14:837-852. doi: 10.2147/OPTH.S207976. eCollection 2020.
10
Comparative study of topical regimen for adenoviral kearoconjunctivitis by 0.1% fluorometholone with and without polyvinyl alcohol iodine.0.1%氟米龙联合或不联合聚乙烯醇碘治疗腺病毒性角结膜炎局部用药方案的对比研究
Jpn J Ophthalmol. 2021 Jan;65(1):107-114. doi: 10.1007/s10384-020-00788-3. Epub 2020 Nov 26.

引用本文的文献

1
An Update on Viral Conjunctivitis Treatment Strategies: A Narrative Literature Review.病毒性结膜炎治疗策略的最新进展:一项叙述性文献综述
Microorganisms. 2025 Jul 22;13(8):1712. doi: 10.3390/microorganisms13081712.
2
Comparison between the Efficacy and Tolerability of Polyvinylpyrrolidone-Iodine Eye Drops 0.6% and 1% in Adenoviral Keratoconjunctivitis: A Randomized Clinical Trial.0.6%和1%聚维酮碘滴眼液治疗腺病毒性角结膜炎的疗效与耐受性比较:一项随机临床试验
J Curr Ophthalmol. 2024 Aug 10;35(4):337-344. doi: 10.4103/joco.joco_251_23. eCollection 2023 Oct-Dec.
3
In praise of povidone-iodine application in ophthalmology.赞碘在眼科学中的应用。
Surv Ophthalmol. 2024 Mar-Apr;69(2):211-223. doi: 10.1016/j.survophthal.2023.11.002. Epub 2023 Nov 8.
4
Characterization of the conserved regions of E1A protein from human adenovirus for reinforcement of cytotoxic T lymphocytes responses to the all genogroups causes ocular manifestation through an in silico approach.通过计算机模拟方法对人腺病毒E1A蛋白保守区域进行表征,以增强细胞毒性T淋巴细胞对所有基因组的反应,这些基因组通过一种计算机模拟方法导致眼部表现。
Iran J Microbiol. 2022 Oct;14(5):746-758. doi: 10.18502/ijm.v14i5.10971.
5
Pentacam corneal densitometry-guided treatment of adenoviral corneal subepithelial infiltrates: a comparative study between transepithelial phototherapeutic keratectomy and topical tacrolimus.Pentacam 角膜密度计引导下治疗腺病毒性角膜上皮下浸润:经上皮光动力角膜切削术与局部他克莫司治疗的对比研究。
Int Ophthalmol. 2021 Jan;41(1):67-77. doi: 10.1007/s10792-020-01553-8. Epub 2020 Aug 27.
6
Virucidal benefits of povidone-iodine use on the ocular surface: a review.聚维酮碘用于眼表的杀病毒作用:综述
BMJ Open Ophthalmol. 2020 Aug 4;5(1):e000509. doi: 10.1136/bmjophth-2020-000509. eCollection 2020.

本文引用的文献

1
Comparison of clinical outcome with different treatment regimens in acute adenoviral keratoconjunctivitis.急性腺病毒性角结膜炎不同治疗方案的临床疗效比较
Eye (Lond). 2017 May;31(5):781-787. doi: 10.1038/eye.2017.4. Epub 2017 Feb 3.
2
Effect of 0.05% topical cyclosporine for the treatment of symptomatic subepithelial infiltrates due to adenoviral keratoconjunctivitis.0.05%局部用环孢素治疗腺病毒性角结膜炎所致症状性上皮下浸润的效果。
Int J Ophthalmol. 2016 Apr 18;9(4):634-5. doi: 10.18240/ijo.2016.04.26. eCollection 2016.
3
Adenoviral keratoconjunctivitis.腺病毒性角结膜炎
Surv Ophthalmol. 2015 Sep-Oct;60(5):435-43. doi: 10.1016/j.survophthal.2015.04.001. Epub 2015 May 5.
4
Povidone iodine in the treatment of adenoviral conjunctivitis in infants.聚维酮碘治疗婴儿腺病毒性结膜炎
Cutan Ocul Toxicol. 2015 Mar;34(1):12-5. doi: 10.3109/15569527.2014.888077. Epub 2014 Mar 31.
5
Ganciclovir ophthalmic gel 0.15%: safety and efficacy of a new treatment for herpes simplex keratitis.更昔洛韦眼用凝胶 0.15%:治疗单纯疱疹性角膜炎的一种新疗法的安全性和疗效。
Curr Eye Res. 2012 Jul;37(7):654-60. doi: 10.3109/02713683.2012.692846. Epub 2012 May 18.
6
Cyclosporine A 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis.环孢素 A1%滴眼液治疗腺病毒性角结膜炎后上皮下浸润。
Cornea. 2011 Sep;30(9):958-61. doi: 10.1097/ICO.0b013e31820cd607.
7
Adenovirus advances: new diagnostic and therapeutic options.腺病毒进展:新的诊断和治疗选择。
Curr Opin Ophthalmol. 2011 Jul;22(4):290-3. doi: 10.1097/ICU.0b013e3283477cb5.
8
Topical treatment with 1% cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis.局部应用 1%环孢素治疗腺病毒性角结膜炎继发的上皮下浸润。
Cornea. 2010 Jun;29(6):638-40. doi: 10.1097/ICO.0b013e3181c33034.
9
A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis.复方聚维酮碘 0.4%/地塞米松 0.1%滴眼液治疗腺病毒性结膜炎。
Adv Ther. 2009 Aug;26(8):776-83. doi: 10.1007/s12325-009-0062-1.
10
Clinical course of epidemic keratoconjunctivitis: evaluation by in vivo confocal microscopy.流行性角结膜炎的临床病程:活体共聚焦显微镜评估
Cornea. 2008 Apr;27(3):263-8. doi: 10.1097/ICO.0b013e31815b7d7d.

稀释聚维酮碘治疗腺病毒性角结膜炎对角膜上皮下浸润发生率的影响。

Effect of diluted povidone iodine in adenoviral keratoconjunctivitis on the rate of subepithelial corneal infiltrates.

作者信息

Altan-Yaycioglu Rana, Sahinoglu-Keskek Nedime, Canan Handan, Coban-Karatas Muge, Ulas Burak

机构信息

Department of Ophthalmology, Baskent University School of Medicine, Adana 01130, Turkey.

出版信息

Int J Ophthalmol. 2019 Sep 18;12(9):1420-1425. doi: 10.18240/ijo.2019.09.08. eCollection 2019.

DOI:10.18240/ijo.2019.09.08
PMID:31544037
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6739576/
Abstract

AIM

To evaluate the clinical characteristics of adenoviral keratoconjunctivitis, the management modalities, as well as the incidence of subepithelial corneal infiltrates (SEI).

METHODS

Patients with characteristic clinical symptoms and signs, who presented to our clinic within the first week of symptoms and received the diagnosis of adenoviral keratoconjunctivitis between January 2013 and April 2016, were included in the study. A total of 211 patients were included in the study. Patients were evaluated for the incidence of clinical signs, late complications, management preferences, and the effect of diluted povidone-iodine (d-PVP-I) 2%.

RESULTS

Patients' mean age was 33.03±14.76y. We observed an increase in the number of cases according to the years. At presentation and/or early follow-up, the clinical signs were conjunctival hyperemia (100%), conjunctival follicules (79.1%), edema of the eyelids (39.3%), chemosis (16.1%), pseudomembrane formation (16.6%), and corneal epitheliopathy (29.9%). During late follow-up 13.3% patients developed conjunctival subepithelial fibrosis, and 39.8% developed SEI. A significant decrease in the incidence of SEI development was observed in patients who used d-PVP-I 2% (=0.032; 33.3% 45.9%, respectively in patients who received d-PVP-I 2% and who did not).

CONCLUSION

Adenoviral keratoconjunctivitis has a tremendous effect on patient's comfort and abilities in short-term. Additionally, almost half of the patients develop visual problems related to SEI. According to our clinical experience, using d-PVP-I 2% in the first days of adenoviral keratoconjunctivitis might be helpful in reducing the risk of SEI as a complication.

摘要

目的

评估腺病毒性角结膜炎的临床特征、治疗方式以及角膜上皮下浸润(SEI)的发生率。

方法

选取2013年1月至2016年4月期间因典型临床症状和体征于症状出现第一周内就诊并被诊断为腺病毒性角结膜炎的患者纳入研究。本研究共纳入211例患者。对患者的临床体征发生率、晚期并发症、治疗偏好以及2%稀释聚维酮碘(d-PVP-I)的效果进行评估。

结果

患者平均年龄为33.03±14.76岁。我们观察到病例数随年份有所增加。就诊时和/或早期随访时,临床体征包括结膜充血(100%)、结膜滤泡(79.1%)、眼睑水肿(39.3%)、球结膜水肿(16.1%)、假膜形成(16.6%)以及角膜上皮病变(29.9%)。在晚期随访中,13.3%的患者出现结膜上皮下纤维化,39.8%的患者出现SEI。使用2% d-PVP-I的患者中SEI发生的发生率显著降低(P=0.032;接受2% d-PVP-I和未接受的患者中分别为33.3%和45.9%)。

结论

腺病毒性角结膜炎在短期内对患者的舒适度和能力有极大影响。此外,几乎一半的患者出现与SEI相关的视力问题。根据我们的临床经验,在腺病毒性角结膜炎发病首日使用2% d-PVP-I可能有助于降低SEI作为并发症的风险。